In anti-PD1-sensitive EL4 and anti-PD1-resistant B16-F10 tumor-bearing mouse models, the combined application of VPA and anti-PD1 clearly increases CD8+ T cell infiltration into tumors and suppresses tumor progression87. The gene discussed is CD8A; the disease is neoplasm.